Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy

Neuromuscular Disorders

Volumn 19, Issue 12, 2009, Pages 833-836

  Kollberg, Gittan ^a   Holme, Elisabeth ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antisense oligonucleotide treatment; Deep intronic mutation; Iron sulphur cluster deficiency myopathy ISCU; Morpholino; Phosphorodiamidate morpholino oligonucleotide (PMO)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE PHOSPHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDE; IRON SULFUR CLUSTER SCAFFOLD PROTEIN; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; ARTICLE; CASE REPORT; HOMOZYGOSITY; HUMAN; HUMAN CELL; INTRON; IRON SULFUR CLUSTER DEFICIENCY MYOPATHY; MYOPATHY; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RNA SPLICING; SKIN FIBROBLAST; SPLICING DEFECT;

BASE SEQUENCE; CELLS, CULTURED; FIBROBLASTS; HUMANS; IRON-SULFUR PROTEINS; MOLECULAR SEQUENCE DATA; MORPHOLINES; MUSCULAR DISEASES; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; SKIN; TIME FACTORS;

EID: 70449536411     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2009.09.011     Document Type: Article

References (16)

1. Mochel F., Knight M.A., Tong W.H., et al. Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. Am J Hum Genet 82 (2008) 652-660
2. Olsson A., Lind L., Thornell L.E., and Holmberg M. Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect. Hum Mol Genet 17 (2008) 1666-1672
3. Kollberg G., Tulinius M., Melberg A., et al. Clinical manifestation and a new ISCU mutation in iron-sulphur cluster deficiency myopathy. Brain 132 (2009) 2170-2179
4. Sun H., and Chasin L.A. Multiple splicing defects in an intronic false exon. Mol Cell Biol 20 (2000) 6414-6425
5. Buratti E., Dhir A., Lewandowska M.A., and Baralle F.E. RNA structure is a key regulatory element in pathological ATM and CFTR pseudoexon inclusion events. Nucleic Acids Res 35 (2007) 4369-4383
6. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31 (2003) 3406-3415
7. Lill R., Dutkiewicz R., Elsasser H.P., et al. Mechanisms of iron-sulfur protein maturation in mitochondria, cytosol and nucleus of eukaryotes. Biochim Biophys Acta 1763 (2006) 652-667
8. Hwang D.M., Dempsey A., Tan K.T., and Liew C.C. A modular domain of NifU, a nitrogen fixation cluster protein, is highly conserved in evolution. J Mol Evol 43 (1996) 536-540
9. Rouault T.A., and Tong W.H. Iron-sulfur cluster biogenesis and human disease. Trends Genet 24 (2008) 398-407
10. Pagani F., and Baralle F.E. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 5 (2004) 389-396
11. Aartsma-Rus A., and van Ommen G.J. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13 (2007) 1609-1624
12. Pros E., Fernandez-Rodriguez J., Canet B., et al. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Hum Mutat 30 (2009) 454-462
13. Rincón A., Aguado C., Desviat L.R., et al. Propionic and methylmalonic acidemia: antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. Am J Hum Genet (2007) 81
14. Heemskerk H.A., de Winter C.L., de Kimpe S.J., et al. In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11 (2009) 257-266
15. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357 (2007) 2677-2686
16. Yokota T., Takeda S., Lu Q.L., et al. A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 66 (2009) 32-38